Survival and tumor burden of mice bearing peritoneally disseminated gastric cancer. Survival and tumor burden of mice bearing peritoneally disseminated.

Slides:

Advertisements

Similar presentations

Antitumor effect of the combination of IL-2 IC and anti–CTLA-4.

Advertisements

Combined A2A receptor and PD-1 blockade is not effective in IFNγ−/− mice. Combined A2A receptor and PD-1 blockade is not effective in IFNγ−/− mice. AT-3ovadim.

H31m1-PDL1 cells form progressively growing tumors in WT mice.

Gr-1+ MDSC in tumor-bearing mice produce IL-6.

Anti-CD96 combines with anti–CTLA-4 or anti–PD-1 to suppress experimental and spontaneous lung metastases. Anti-CD96 combines with anti–CTLA-4 or anti–PD-1.

Effect of MI-773 and/or cisplatin in a preclinical model of ACC

Activity of MAC-321 (i. v. and p. o

Mouse lymphoma model. Mouse lymphoma model. A, EL-Arf−/− cells (1 × 106) were tail-vein injected into C57BL/6 mice. LNIWC imaging was separated into 2.

Protection from 4T1 tumor rechallenge in treated mice.

Dox administration was required for Tet-CD19CAR T cells to show a suppressive function against a CD19+ tumor in vivo. Dox administration was required for.

Mice immunized twice with RRBC showed superior protection to tumor challenge with αGal-positive MC38 colon carcinoma cells compared with mock-immunized.

In vivo assessment of synergistic activity of MV-CEA and RT in a U87 s

Effect of HA on hematopoietic recovery in tumor-bearing mice.

GS87 demonstrates efficacy in a circulating AML mouse model system.

coTCRcys-transduced T cells control tumor growth in vivo.

A, Overall survival of patients treated with CAR T cells (black line; n = 15). A, Overall survival of patients treated with CAR T cells (black line; n.

EHop-016 and INK128 treatment of myxofibrosarcoma xenografts in NSG mice. EHop-016 and INK128 treatment of myxofibrosarcoma xenografts in NSG mice. A,

SBC-5 miR-335+ xenografts abrogated completely, or in part, skeletal osteolytic lesions in humanized NOD/SCID IL2Rγnull immunodeficient mice. SBC-5 miR-335+

Anti-Flk-1 treatment inhibits growth of s. c. 4T1 and B16 tumors. s. c

Matriptase-2 inhibited breast tumor development in vivo.

A, one-step viral growth curves: RT treatment increased the virus yield in MV-CEA–treated U87 cells by up to 2 log as compared with MV-CEA infection only.

Experimental metastasis inhibition by primary tumors is mediated by NK cells and IFNγ. Experimental metastasis inhibition by primary tumors is mediated.

Volume 20, Issue 4, Pages (April 2012)

Bcl-xL expression in tumors antagonizes the therapeutic efficiency of ERBB2 downregulation. Bcl-xL expression in tumors antagonizes the therapeutic efficiency.

Effect of therapy with S247 on the development of liver metastases after 14 and 21 days of tumor growth. Effect of therapy with S247 on the development.

Antitumor activity of temozolomide (30 mg/kg for 5 days), talazoparib (0.25 mg/kg twice daily for 5 days), or in combination against xenograft models sensitive.

The antitumor and antimetastatic properties of PF in the MX1 orthotopic model. The antitumor and antimetastatic properties of PF in the.

PD-L1 expressed on edited T3 sarcoma cells prevents their immune elimination. PD-L1 expressed on edited T3 sarcoma cells prevents their immune elimination.

Induction of cytotoxic activity in humanized SCC3 tumor-bearing mice treated with anti-PD-1 antibody. Induction of cytotoxic activity in humanized SCC3.

IDO deficiency delays the development of pulmonary metastases.

In vivo tumorigenicity of MKN-1 cells with sustained suppression of HDAC2. In vivo tumorigenicity of MKN-1 cells with sustained suppression of HDAC2. A,

ADU-S100–mediated tumor clearance is dependent on CD4+, CD8+ T cells, and NK cells. ADU-S100–mediated tumor clearance is dependent on CD4+, CD8+ T cells,

5FU-induced specific activation of CD8+ T cells.

Alkaline Comet assay showing DNA break formation after 6-TG treatment, implying more SSBs generated in MMR+ cells. Alkaline Comet assay showing DNA break.

ESKM is superior to ESK1 in vivo, and is effective against multiple tumor models. ESKM is superior to ESK1 in vivo, and is effective against multiple tumor.

Efficacy of DC therapy is synergistically enhanced by combination therapy with TAM depletion in mesothelioma mouse models. Efficacy of DC therapy is synergistically.

A protracted ketogenic diet increases radiation response in H292 lung cancer xenografts given conventional fractionated radiation. A protracted ketogenic.

Nested RT-PCR of Mammaglobin and CK19 mRNA in plasma and circulating cells of controls (C) and patients (T) with breast cancer. Nested RT-PCR of Mammaglobin.

GM-CSF is required for CA-MSC–induced tumor metastasis.

Influenza vaccine enhances NK cell function through IFN-α.

The responses of H292 and A549 lung cancer xenografts to hypofractionated radiation were enhanced by the ketogenic diet. The responses of H292 and A549.

Activity of a chemically modified miR-21 inhibitor in human bladder cancer xenografts. Activity of a chemically modified miR-21 inhibitor in human bladder.

Mean cell number in small intestinal crypt (a), small intestinal villus (b), and midcolonic crypt (c) of BALB/c (♦) and DBA/2 (▪) mice after two injections.

In vivo bioluminescence imaging of primary tumors and tumor metastasis

Systemic reovirus treatment targets disseminated human myeloma in vivo

A to C, MetMAb shows strong antitumor activity in the KP4 orthotopic model of pancreatic cancer by ultrasound. A to C, MetMAb shows strong antitumor activity.

PK profile of OTL78. PK profile of OTL78. A, Representative time-dependent whole-body fluorescence images over white light images of a mouse bearing 22Rv1.

Mean weight change from original weight of (a) BALB/c (b) DBA/2 mice after one (♦) or two (▴) injections of 10 mg/kg and one (▪) or two (×) injections.

Comparison of in vivo activity of 4D5scFvZZ and 4D5scFv.

A, capsid modifications increase the infectivity of gastric cancer cell lines. A, capsid modifications increase the infectivity of gastric cancer cell.

Tumor protection induced by therapeutic PLG vaccination in combination with blockade antibodies. Tumor protection induced by therapeutic PLG vaccination.

Immunotherapy of NK-92-S3KD increases anticancer effector productions in HepG2-bearing mice. Immunotherapy of NK-92-S3KD increases anticancer effector.

CDV potentiates the antitumor effect of ionizing radiation in mice intracerebrally implanted with human glioblastoma cells. CDV potentiates the antitumor.

[123I]MIBG scintigraphy of MSTO-211H pleural tumors.

RhuαVEGF and rhuαVEGF/paclitaxel mediated growth inhibition in an androgen-independent prostate cancer xenograft model. rhuαVEGF and rhuαVEGF/paclitaxel.

Biodistributions 24 hours after injection of different 177Lu-chCE7F(ab′)2 conjugates ( MBq, 13 μg) in tumor-bearing nude mice: effect of the number.

TAE-684 effectively inhibits the growth of H3122 in vivo.

Efficacy of KM100 and/or MTX in BALB/c mice bearing subcutaneous TUBO tumors. Efficacy of KM100 and/or MTX in BALB/c mice bearing subcutaneous TUBO tumors.

Effect of MZ treatment on lung colony formation in an experimental metastasis. Effect of MZ treatment on lung colony formation in an experimental metastasis.

Increased accumulation of pmel-1 T cells to tumor sites and enhanced antitumor immune response in mice receiving ACT combined with anti-PD-1 antibody treatment.

Proliferation of TA3-Ha and TA3-St cells in vitro and in vivo.

PDL192 and inhibit the growth of xenograft tumors.

A, antitumor activity of temozolomide (30 mg/kg for 5 days), talazoparib (0.25 mg/kg twice daily for 5 days), or in combination against “sensitive” Ewing.

Survival RR enhancement according to the specific protocol in treated mice. Survival RR enhancement according to the specific protocol in treated mice.

Bioluminescent imaging of NALM-6(GFP-FFLuc) tumor cells after weekly CAR+ T-cell treatment for 4 wks. Bioluminescent imaging of NALM-6(GFP-FFLuc) tumor.

Cy5.5-labeled anti-B7-H4 BsAb (Fab-scFv) localization in tumor-bearing mice and BsAb half-life in mouse blood. Cy5.5-labeled anti-B7-H4 BsAb (Fab-scFv)

Enhanced antitumor effects with combination IL21 and anti–PD-1/anti–Tim-3 therapy. Enhanced antitumor effects with combination IL21 and anti–PD-1/anti–Tim-3.

Recruitment of CD8+, CD4+, and Foxp3+ cells into oral lesions in response to anti–PD-1 treatment. Recruitment of CD8+, CD4+, and Foxp3+ cells into oral.

Depletion of CD8+, CD4+, and Ly6G+ cells in subcutaneous TUBO tumor-bearing BALB/c mice treated with KM100 + MTX. Depletions were conducted by intraperitoneal.

PD-L1 expression is not associated with PTEN expression status in melanomas. PD-L1 expression is not associated with PTEN expression status in melanomas.

Presentation transcript:

Survival and tumor burden of mice bearing peritoneally disseminated gastric cancer. Survival and tumor burden of mice bearing peritoneally disseminated gastric cancer. MKN-28 cells were injected i.p. into severe combined immunodeficiency mice, and tumor was allowed to develop for 10 days. Mice were treated i.p. with CRAds or replication-deficient control virus and followed for survival. A, all oncolytic viruses significantly improved the survival of mice over mock (P < 0.0005) and Ad5luc1 (P < 0.05) injected mice. B, 50 days after injecting the cells, serum samples were collected from the tail vein to measure tumor marker βhCG. Lotta Kangasniemi et al. Clin Cancer Res 2006;12:3137-3144 ©2006 by American Association for Cancer Research